Die folgenden Links führen aus den jeweiligen lokalen Bibliotheken zum Volltext:
Alternativ können Sie versuchen, selbst über Ihren lokalen Bibliothekskatalog auf das gewünschte Dokument zuzugreifen.
Bei Zugriffsproblemen kontaktieren Sie uns gern.
SSRN
In: ALZA Conference Series 2
Section I — Temporal Organization in Biosystems -- The Biological Time Scale -- Temporal and Hierarchical Organization in Biosystems -- Time and Timelessness in Biological Clocks -- Section II — Temporal Aspects of Subcellular Synthesis -- Sequential Assembly of Virus Particles -- Temporal Aspects of Macromolecular Synthesis in Eukaryotic Cells -- Section III — Temporal Aspects of Organ System Function -- Hormonal Control of the Menstrual Cycle and Ovulation in the Rhesus Monkey -- Section IV — Temporal Patterns and Therapeutics -- Pharmacokinetic Aspects of Controlled Drug Delivery Systems -- Cell Proliferation Characteristics and Cancer Chemotherapy -- Chronopharmacology in the Treatment of Hypertension with Diuretics -- Testosterone Polydimethylsiloxane Implants and Contraception in Male Rabbits -- Progress towards an Implantable Glucose Sensor and an Artificial Beta Cell -- Epilogue.
In: Futures: the journal of policy, planning and futures studies, Band 27, Heft 9-10, S. 921-926
ISSN: 0016-3287
In: Futures, Band 27, Heft 9-10, S. 993-1003
As we enter the decade of the 2010s, regulatory agencies in the United States and the European Union are currently establishing a variety of new initiatives, guidances and guidelines that aim to facilitate the development and approval of therapeutics, including antibodies.
BASE
In: Drug Enforcement and Policy Center, No. 10, August 2019
SSRN
Working paper
"Preface" -- "Contents" -- "About the Editors" -- "List of Contributors" -- "1 Introduction to Novel Therapeutic Carriers" -- "Abstract" -- "1 Introduction" -- "2 Type of New Drug Carriers Systems" -- "2.1 Transdermal Drug Delivery System" -- "2.2 Carrier-Based Delivery Systems" -- "2.3 Variable Release Delivery Systems" -- "2.3.1 Osmotic Pump-Based Drug Delivery Systems" -- "2.3.2 Reservoir-Based System" -- "2.3.3 Matrix-Based Drug Delivery System" -- "3 Preparation of Particulate Drug Delivery Systems" -- "3.1 Dispersion Method" -- "3.2 Solvent Evaporation Method" -- "3.3 Emulsification or Solvent Diffusion Method" -- "3.4 Coacervation Method" -- "3.5 Polymerization Method" -- "3.6 Spray Drying and Congealing" -- "3.7 Emulsification-Cross-Linking Method" -- "3.8 Reverse Micellar Method" -- "3.9 Supercritical Method" -- "4 Release Kinetics from Nondegradable Polymeric Matrices" -- "5 Release Kinetics from Biodegradable Polymeric Matrices" -- "6 Concluding Remarks" -- "References" -- "2 The Development and Achievement of Polymeric Nanoparticles for Cancer Drug Treatment" -- "Abstract" -- "1 Introduction" -- "1.1 Physiological Conditions of Tumor Tissues" -- "1.2 Rationale of Cancer Nanotechnology" -- "1.3 Important Considerations in Nanoparticle-Based Delivery for Cancer Treatment" -- "1.3.1 Passive Targeting of Nanoparticles: Enhanced Permeability and Retention (EPR) Effect" -- "1.3.2 Active Targeting of Nanoparticles" -- "2 Polymeric Nanocarriers for Therapeutic Applications in Cancer" -- "2.1 Polymeric Micelles for Therapeutic Applications in Cancer" -- "2.1.1 Doxorubicin (DOX) Conjugated Polymeric Micelles" -- "2.1.2 Paclitaxel (PTX) Conjugated Polymeric Micelles" -- "2.1.3 Other Chemotherapeutic Drugs Conjugated Polymeric Micelles" -- "2.2 Polymeric Nanoparticles for Therapeutic Applications in Cancer
As the prevalence of Alzheimer's disease (AD) grows, so do the costs it imposes on society. Scientific, clinical, and financial interests have focused current drug discovery efforts largely on the single biological pathway that leads to amyloid deposition. This effort has resulted in slow progress and disappointing outcomes. Here, we describe a "portfolio approach" in which multiple distinct drug development projects are undertaken simultaneously. Although a greater upfront investment is required, the probability of at least one success should be higher with "multiple shots on goal," increasing the efficiency of this undertaking. However, our portfolio simulations show that the risk-adjusted return on investment of parallel discovery is insufficient to attract private-sector funding. Nevertheless, the future cost savings of an effective AD therapy to Medicare and Medicaid far exceed this investment, suggesting that government funding is both essential and financially beneficial.
BASE
As the prevalence of Alzheimer's disease (AD) grows, so do the costs it imposes on society. Scientific, clinical, and financial interests have focused current drug discovery efforts largely on the single biological pathway that leads to amyloid deposition. This effort has resulted in slow progress and disappointing outcomes. Here, we describe a "portfolio approach" in which multiple distinct drug development projects are undertaken simultaneously. Although a greater upfront investment is required, the probability of at least one success should be higher with "multiple shots on goal," increasing the efficiency of this undertaking. However, our portfolio simulations show that the risk-adjusted return on investment of parallel discovery is insufficient to attract private-sector funding. Nevertheless, the future cost savings of an effective AD therapy to Medicare and Medicaid far exceed this investment, suggesting that government funding is both essential and financially beneficial.
BASE
© 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works The nucleus contains diverse phase-separated condensates that compartmentalize and concentrate biomolecules with distinct physicochemical properties. Here, we investigated whether condensates concentrate small-molecule cancer therapeutics such that their pharmacodynamic properties are altered. We found that antineoplastic drugs become concentrated in specific protein condensates in vitro and that this occurs through physicochemical properties independent of the drug target. This behavior was also observed in tumor cells, where drug partitioning influenced drug activity. Altering the properties of the condensate was found to affect the concentration and activity of drugs. These results suggest that selective partitioning and concentration of small molecules within condensates contributes to drug pharmacodynamics and that further understanding of this phenomenon may facilitate advances in disease therapy.
BASE
In: Therapeutic Cultures
The Open Access version of this book, available at https://www.taylorfrancis.com/books/e/9781351233392, has been made available under a Creative Commons Attribution-Non Commercial-No Derivatives 4.0 license. This volume examines the ways in which people engage with therapeutic practices, such as life coaching, mindfulness, complementary and alternative medicine, sex and relationship counselling, spiritual healing and self-tracking. It investigates how human and non-human actors, systems of thought and practice are assembled and interwoven in therapeutic engagements, and traces the situated, material and political dimensions of these engagements. By focusing on lived experiences through ethnographically informed case studies, the book elucidates the diverse forms, meanings and embodied effects of therapeutic engagements in different settings, as well as their potential for both oppressive and subversive social change. In this way, Assembling Therapeutics contributes to our understanding of multiple modes of healing, self-knowledge and power in contemporary societies.
In: Bulletin of the World Health Organization: the international journal of public health = Bulletin de l'Organisation Mondiale de la Santé, Band 93, Heft 2, S. 70-71
ISSN: 1564-0604
Intro -- Title Page -- Chapter 1 -- Developments in Human Longevity: A State-of-the-Specialty Report -- Ronald Klatz, M.D., D.O., President -- Robert Goldman, M.D., Ph.D., D.O., FAASP, Chairman -- Chapter 2 -- Healing the Mind and Body with Food: A Personal Experience -- Tana Amen, BSN, RN -- Chapter 3 -- Arterial Inflammation, Autophagy, and Senescence: Relationship to Aging and Cardiovascular Disease -- Bradley Field Bale, M.D. -- Chapter 4 -- Evoked Potentials and Neuropsychological Tests Validate Positron Emission Topography (PET) Brain Metabolism in Cognitively Impaired Patients -- Eric R. Braverman, M.D., Kenneth Blum, Ph.D., Uma J. Damle, BA, Mallory Kerner, BS, Kristina Dushaj, BA, and Marlene Oscar-Berman, Ph.D. -- Chapter 5 -- Hormonal Correlations in Female Menopausal Patients as a Function of Somatic and Neurological Symptom Clusters: An Exploratory Development of a Multi-Hormonal Map for Bioidentical Replacement Therapy (MHRT) -- Eric R Braverman. M.D., Kenneth Perrine, Uma J Damle, Stella Savarimuth, Swetha Yeldandi, Mallory Kerner, Kristina Dushaj, Elizabeth Mo, Pooja Reddy, Pavan Reddy, Mona Li, Danielle Stratton, Kenneth Blum, Ph.D. -- Chapter 6 -- The Importance of Nitric Oxide for Sexual and Exercise Performance and its Role in Adenosine Triphosphate Production -- Nathan S. Bryan, Ph.D. -- Chapter 7 -- Detoxify for Life -- John Cline, M.D., BSc, IFMCP -- Chapter 8 -- The Role of Intravenous Magnesium EDTA (MgNa2 EDTA) Chelation Therapy in Ameliorating and Preventing Chronic Diseases Associated with Aging -- Martin Dayton, D.O., M.D. -- Chapter 9 -- Chronic Disease and Obesity: The Role of Food Sensitivities -- Tania Tyles Dempsey, MD, ABIHM -- Chapter 10 -- Dyslipidemia Truths and Myths -- Mark Houston MD, MS, MSc, ABAARM, FAARM, FACP, FAHA, FASH, FACN -- Chapter 11.
In the United States, the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act continue to promote clinical trials in pediatric populations across all age ranges. In 2014 and 2015, over 70 changes were made to drug labels with updates on information regarding pediatric populations. Additionally, multiple new therapies have received first-approvals for the treatment of pediatric indications ranging form rare genetic metabolic diseases to oncology. In the European Union, there have been more than 30 new authorizations for medicines used in children and 130 approved pediatric investigation plans. Despite the progress that has been made over the last two years, much work remains to further the development of safe and effective therapies for pediatric patients.
BASE